European Journal of Cancer Supplements This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
Publication date: December 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 2 Author(s): Christina Fotopoulou Most patients with recurrent ovarian cancer (ROC) undergo a series of remissions and recurrences, therefore the additive or cumulative toxicity of chemotherapy must be factored into their treatment plan. There are challenges in defining tailored therapeutic approaches, including optimal timing and drug sequencing management strategies to treat patients with ROC. This is particularly as new cytotoxic drugs and biological agents become available. Many of these drugs are associated with increa...
Source: European Journal of Cancer Supplements - January 15, 2015 Category: Cancer & Oncology Source Type: research

Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient
Publication date: December 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 2 Author(s): Nicoletta Colombo The choice of second-line chemotherapy in patients with recurrent ovarian cancer (ROC) is complex, with several factors to be considered, the most important of which is the length of the platinum-free treatment interval (PFI). Recently ROC patients have been further stratified into platinum sensitive (PS), partially platinum sensitive (PPS) and platinum resistant (PR) subgroups depending on the length of the PFI. Response to second-line therapy, progression-free survival (PFS) and overall surv...
Source: European Journal of Cancer Supplements - January 15, 2015 Category: Cancer & Oncology Source Type: research

Introduction to managing patients with recurrent ovarian cancer
Publication date: December 2014 Source:European Journal of Cancer Supplements, Volume 12, Issue 2 Author(s): Hani Gabra Ovarian cancer is the 5th most common cancer found in women in the UK. It is the leading cause of death from gynaecological cancer, and is the 4th most common cause of cancer death among UK women. Similar to the majority of other cancers, relative survival rates for ovarian cancer are improving, although 5-year mortality rates remain stubbornly low. The stage of the disease at diagnosis is the single most important determinant of ovarian cancer survival, as many patients first present with advanced d...
Source: European Journal of Cancer Supplements - January 15, 2015 Category: Cancer & Oncology Source Type: research

Molecular profile of lung cancer in never smokers
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Janakiraman Subramanian , Ramaswamy Govindan Tobacco smoking is the most common cause of lung cancer, but approximately 10–25% of patients with lung cancer are life-long never smokers. The cause of lung cancer in never smokers is unknown, although tobacco-smoke exposure may play a role in some of these patients. Lung cancer that develops in the absence of significant tobacco-smoke exposure appears to be a unique disease entity with novel genomic and epigenomic alterations and activation of molecular pathway...
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Prevention – Passive smoking and pregnancy
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Tim S. Nawrot , Bianca Cox , Bram G. Janssen , Michelle Plusquin (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Lung cancer in non-smokers
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Rolf A. Stahel (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Drug-associated delirium in cancer patients
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Augusto Caraceni (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Chemotherapy-related changes in cognitive functioning
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Sanne B. Schagen , Jeffrey S. Wefel (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Anxiety and sleep disorders in cancer patients
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Maria Die Trill (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Depression in cancer patients
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): S. Dauchy , S. Dolbeault , M. Reich (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Mood disorders in cancer patients
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): O. Husson (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Integrating metastasectomy and stereotactic radiosurgery in the treatment of metastatic renal cell carcinoma
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Axel Bex (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Manuela Schmidinger (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Does a reasonable treatment approach beyond second-line exist?
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Bernard Escudier (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research

Individualising treatment choices in a crowded treatment algorithm
Publication date: September 2013 Source:European Journal of Cancer Supplements, Volume 11, Issue 2 Author(s): Rosalie Fisher , James Larkin (Source: European Journal of Cancer Supplements)
Source: European Journal of Cancer Supplements - October 13, 2014 Category: Cancer & Oncology Source Type: research